HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Thursday, MarketBeat reports. They currently have a $120.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 41.71% from the company’s current price.

A number of other analysts have also recently commented on ORKA. BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $128.91.

Oruka Therapeutics Stock Down 0.9%

Shares of NASDAQ:ORKA traded down $0.81 during mid-day trading on Thursday, reaching $84.68. 154,197 shares of the stock were exchanged, compared to its average volume of 1,098,862. The company has a market cap of $5.61 billion, a P/E ratio of -41.66 and a beta of -0.34. The stock’s 50 day simple moving average is $96.83 and its 200-day simple moving average is $75.69. Oruka Therapeutics has a one year low of $15.00 and a one year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, CEO Lawrence Klein sold 2,452 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total transaction of $234,680.92. Following the completion of the transaction, the chief executive officer owned 923,128 shares in the company, valued at $88,352,580.88. The trade was a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the sale, the insider owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 122,950 shares of company stock worth $11,528,806 over the last three months. 23.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics during the second quarter worth about $474,916,000. Jupiter Topco LLC purchased a new position in shares of Oruka Therapeutics in the second quarter worth $130,968,000. Remedium Capital Partners LLC lifted its position in Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after acquiring an additional 13,247 shares during the period. Perceptive Advisors LLC increased its holdings in shares of Oruka Therapeutics by 16.4% in the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock valued at $44,753,000 after purchasing an additional 208,480 shares during the period. Finally, Avidity Partners Management LP raised its stake in shares of Oruka Therapeutics by 15.1% in the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after purchasing an additional 100,000 shares during the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Encouraging ORKA-001 psoriasis data: Results from the Phase 2a EVERLAST-A trial showed that psoriasis responses deepened through week 28, supporting the durability and potential competitive profile of ORKA-001. Oruka Announces Positive Week 28 Results
• Positive Sentiment: Analyst support remains strong: Wedbush reaffirmed its “Outperform” rating with a $165 price target, while HC Wainwright maintained a “Buy” rating and a $120 target. UBS also said ORKA-001 retains a competitive profile following the clinical update. Wedbush Rating and Price Target
• Positive Sentiment: Pipeline expansion: Oruka provided an update on its ongoing randomized, placebo-controlled study of ORKA-002 in hidradenitis suppurativa, giving investors an additional potential clinical catalyst beyond psoriasis. ORKA-002 Trial Progress
• Neutral Sentiment: Short-interest data appears inconclusive: A report described a sharp increase in short interest, but also listed total short interest at zero shares and a zero-day short-interest ratio, making the figures difficult to interpret as a meaningful trading signal.
• Negative Sentiment: Safety disclosures overshadowed efficacy: Although ORKA-001 delivered deeper psoriasis clearance at week 28, safety information appears to have prompted investor caution. Reports noted that the stock fell even as the efficacy results improved, suggesting expectations were already high and the market wants greater clarity on the treatment’s risk-benefit profile. ORKA Stock and Week 28 Data

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.